Skip to main content
Download PDF
- Main
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Published Web Location
https://doi.org/10.1016/j.euo.2024.02.010Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.